226 related articles for article (PubMed ID: 19564785)
21. Is there a case for anti-HER2 therapy without chemotherapy in early breast cancer?
Constantinidou A; Smith I
Breast; 2011 Oct; 20 Suppl 3():S158-61. PubMed ID: 22015286
[TBL] [Abstract][Full Text] [Related]
22. Prognostic factors of brain metastases from breast cancer: impact of targeted therapies.
Braccini AL; Azria D; Thezenas S; Romieu G; Ferrero JM; Jacot W
Breast; 2013 Oct; 22(5):993-8. PubMed ID: 23831232
[TBL] [Abstract][Full Text] [Related]
23. HER-2/neu expression in primary and metastatic breast cancer.
Lower EE; Glass E; Blau R; Harman S
Breast Cancer Res Treat; 2009 Jan; 113(2):301-6. PubMed ID: 18273700
[TBL] [Abstract][Full Text] [Related]
24. Clinicopathologic significance of the basal-like subtype of breast cancer: a comparison with hormone receptor and Her2/neu-overexpressing phenotypes.
Kim MJ; Ro JY; Ahn SH; Kim HH; Kim SB; Gong G
Hum Pathol; 2006 Sep; 37(9):1217-26. PubMed ID: 16938528
[TBL] [Abstract][Full Text] [Related]
25. Phase II study of the antibody drug conjugate trastuzumab-DM1 for the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer after prior HER2-directed therapy.
Burris HA; Rugo HS; Vukelja SJ; Vogel CL; Borson RA; Limentani S; Tan-Chiu E; Krop IE; Michaelson RA; Girish S; Amler L; Zheng M; Chu YW; Klencke B; O'Shaughnessy JA
J Clin Oncol; 2011 Feb; 29(4):398-405. PubMed ID: 21172893
[TBL] [Abstract][Full Text] [Related]
26. Clinical relevance of HER2 overexpression/amplification in patients with small tumor size and node-negative breast cancer.
Curigliano G; Viale G; Bagnardi V; Fumagalli L; Locatelli M; Rotmensz N; Ghisini R; Colleoni M; Munzone E; Veronesi P; Zurrida S; Nolè F; Goldhirsch A
J Clin Oncol; 2009 Dec; 27(34):5693-9. PubMed ID: 19884553
[TBL] [Abstract][Full Text] [Related]
27. Phase II study of weekly intravenous trastuzumab (Herceptin) in patients with HER2/neu-overexpressing metastatic breast cancer.
Baselga J; Tripathy D; Mendelsohn J; Baughman S; Benz CC; Dantis L; Sklarin NT; Seidman AD; Hudis CA; Moore J; Rosen PP; Twaddell T; Henderson IC; Norton L
Semin Oncol; 1999 Aug; 26(4 Suppl 12):78-83. PubMed ID: 10482197
[TBL] [Abstract][Full Text] [Related]
28. HER2 protein and gene variation between primary and metastatic breast cancer: significance and impact on patient care.
Fabi A; Di Benedetto A; Metro G; Perracchio L; Nisticò C; Di Filippo F; Ercolani C; Ferretti G; Melucci E; Buglioni S; Sperduti I; Papaldo P; Cognetti F; Mottolese M
Clin Cancer Res; 2011 Apr; 17(7):2055-64. PubMed ID: 21307144
[TBL] [Abstract][Full Text] [Related]
29. Trastuzumab clears HER2/neu-positive isolated tumor cells from bone marrow in primary breast cancer patients.
Rack B; Jückstock J; Günthner-Biller M; Andergassen U; Neugebauer J; Hepp P; Schoberth A; Mayr D; Zwingers T; Schindlbeck C; Friese K; Janni W
Arch Gynecol Obstet; 2012 Feb; 285(2):485-92. PubMed ID: 21717141
[TBL] [Abstract][Full Text] [Related]
30. Quantitation of p95HER2 in paraffin sections by using a p95-specific antibody and correlation with outcome in a cohort of trastuzumab-treated breast cancer patients.
Sperinde J; Jin X; Banerjee J; Penuel E; Saha A; Diedrich G; Huang W; Leitzel K; Weidler J; Ali SM; Fuchs EM; Singer CF; Köstler WJ; Bates M; Parry G; Winslow J; Lipton A
Clin Cancer Res; 2010 Aug; 16(16):4226-35. PubMed ID: 20664024
[TBL] [Abstract][Full Text] [Related]
31. The role of trastuzumab in the management of HER2-positive metastatic breast cancer: an updated review.
Tokuda Y; Suzuki Y; Saito Y; Umemura S
Breast Cancer; 2009; 16(4):295-300. PubMed ID: 19609647
[TBL] [Abstract][Full Text] [Related]
32. Retrospective evaluation of clinical outcomes in patients with HER2-positive advanced breast cancer progressing on trastuzumab-based therapy in the pre-lapatinib era.
Montemurro F; Redana S; Viale G; Sanna G; Donadio M; Valabrega G; del Curto B; Bottini A; Botti G; dei Tos AP; Jacomuzzi ME; Di Bonito M; Danese S; Clavarezza M; Kulka J; Di Palma S; Durando A; Sapino A; Aglietta M
Clin Breast Cancer; 2008 Oct; 8(5):436-42. PubMed ID: 18952558
[TBL] [Abstract][Full Text] [Related]
33. Pathological complete response and prognosis in patients receiving neoadjuvant paclitaxel and trastuzumab with and without anthracyclines for stage II and III, HER2-positive operable breast cancer: a single-institute experience.
Horiguchi J; Oyama T; Takata D; Rokutanda N; Nagaoka R; Odawara H; Tokiniwa H; Tozuka K; Kikuchi M; Sato A; Takeyoshi I
Anticancer Res; 2011 Sep; 31(9):3041-6. PubMed ID: 21868556
[TBL] [Abstract][Full Text] [Related]
34. Biological subtypes and survival outcomes in breast cancer patients with brain metastases (study of the Anatolian Society of Medical Oncology).
Kaplan MA; Isikdogan A; Koca D; Kucukoner M; Gumusay O; Yildiz R; Dayan A; Demir L; Geredeli C; Kocer M; Arslan UY; Inal A; Unal OU; Mert AG; Bilici M; Ozkan M; Elkiran ET; Yaman S; Durnalı AG; Suner A; Alici S; Tarhan MO; Boruban C; Urakci Z; Buyukberber S
Oncology; 2012; 83(3):141-50. PubMed ID: 22814315
[TBL] [Abstract][Full Text] [Related]
35. HER-2/neu status of primary breast cancer and corresponding metastatic sites in patients with advanced breast cancer treated with trastuzumab-based therapy.
Pectasides D; Gaglia A; Arapantoni-Dadioti P; Bobota A; Valavanis C; Kostopoulou V; Mylonakis N; Karabelis A; Pectasides M; Economopoulos T
Anticancer Res; 2006; 26(1B):647-53. PubMed ID: 16739334
[TBL] [Abstract][Full Text] [Related]
36. Overall survival benefit with lapatinib in combination with trastuzumab for patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: final results from the EGF104900 Study.
Blackwell KL; Burstein HJ; Storniolo AM; Rugo HS; Sledge G; Aktan G; Ellis C; Florance A; Vukelja S; Bischoff J; Baselga J; O'Shaughnessy J
J Clin Oncol; 2012 Jul; 30(21):2585-92. PubMed ID: 22689807
[TBL] [Abstract][Full Text] [Related]
37. Impact of FOXA1 expression on the prognosis of patients with hormone receptor-positive breast cancer.
Hisamatsu Y; Tokunaga E; Yamashita N; Akiyoshi S; Okada S; Nakashima Y; Aishima S; Morita M; Kakeji Y; Maehara Y
Ann Surg Oncol; 2012 Apr; 19(4):1145-52. PubMed ID: 21984487
[TBL] [Abstract][Full Text] [Related]
38. [Current situation and issues regarding preoperative chemotherapy for HER2-positive breast cancer].
Mizutani M; Masuda N; Abe H; Yamamura J; Yasojima H; Kodama Y; Umeda T; Kurumi Y; Mano M; Tani T
Gan To Kagaku Ryoho; 2012 Dec; 39(13):2521-6. PubMed ID: 23235172
[TBL] [Abstract][Full Text] [Related]
39. Prognosis of metastatic breast cancer subtypes: the hormone receptor/HER2-positive subtype is associated with the most favorable outcome.
Lobbezoo DJ; van Kampen RJ; Voogd AC; Dercksen MW; van den Berkmortel F; Smilde TJ; van de Wouw AJ; Peters FP; van Riel JM; Peters NA; de Boer M; Borm GF; Tjan-Heijnen VC
Breast Cancer Res Treat; 2013 Oct; 141(3):507-14. PubMed ID: 24104881
[TBL] [Abstract][Full Text] [Related]
40. Risk factors for brain relapse in HER2-positive metastatic breast cancer patients.
Duchnowska R; Dziadziuszko R; Czartoryska-Arłukowicz B; Radecka B; Szostakiewicz B; Sosińska-Mielcarek K; Karpińska A; Starosławska E; Kubiatowski T; Szczylik C
Breast Cancer Res Treat; 2009 Sep; 117(2):297-303. PubMed ID: 19130219
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]